Clinical Trial Update: Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares stereotactic body radiotherapy to standard of care for oligoprogressive metastatic prostate cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Oligoprogressive Metastatic Disease

Snippet

Sponsor: University Health Network, Toronto | Conditions: Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease | Phase 2 | Status: RECRUITING